News
Jan 13 (Reuters) - U.S. based-Regeneron Pharmaceuticals Inc and Germany's Bayer AG said they would co-develop an antibody for use in combination with Eylea, their treatment for a form of age ...
Bayer is confident to continue its market leadership in the retinal disease space and establish Eylea 8 mg as the next standard of care in retinal diseases given its unparalleled clinical profile. As ...
Bayer has revealed ... be able to adjust the treatment schedule to the individual needs of every patient and reduce the burden of injections for people with wet AMD. Results of the ALTAIR study were ...
Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...
FRANKFURT, Sept 8 (Reuters) - Bayer (BAYGn.DE), opens new tabsaid on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), opens new tab, has been shown to work ...
New treatment allows dosing every other month following three initial monthly injections in wet AMD patients Berlin, November 27, 2012 – Bayer HealthCare announced today that EYLEA ...
In February 2025, Bayer submitted an application to EMA to expand treatment intervals to up to 6 months with Eylea 8 mg for the treatment of nAMD and DME based on clinical evidence from the PULSAR and ...
Bayer has licensed exclusive marketing rights outside the United States, where the companies share equal profits from the sales of Eylea. Eylea’s intravitreal injection 40 mg/mL has been approved for ...
Eylea HD is a higher dose of an existing drug, aflibercept, that’s already used to treat wet macular degeneration and diabetic macular edema. Americans diagnosed with wet age-related macular ...
(RTTNews) - Bayer AG (BYR.L) on Thursday announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the market authorization of Eylea 8 mg ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback